Showing posts with label Immucor (BLUD). Show all posts
Showing posts with label Immucor (BLUD). Show all posts

Tuesday, July 5, 2011

Did I make a BLUD-dy mistake?

Immucor (BLUD), a company I thought I had a lot of things to like, just announced that it is getting bought out for a cool 30% premium.  Not bad for a ~3 month time frame.  Too bad I never purchased it.  Stocks, and women for that matter, are a lot like buses.  If you miss one, another will be along in 10 minutes.  There were a couple factors that are worth mentioning that maybe indicated this buyout would happen, although it's not something I would actively seek in an investment.  Looking at the role a CEO can play in how an investment plays out is worth digging into.

The CEO until last month was also the founder.  He took this company from nothing to a $1.2bn company.  It is hard to depart and it's hard to maybe affect the kind of change necessary when the company needs to put their shoulder to the wheel during hard times.  This is a qualitative factor I hadn't really taken into account before, which is why I tend to shy away from a company like this.  The Buffett's, Sequoia's, and Simpson's are just so much better at identifying the really good companies with a margin of safety than an amateur.

I identified BLUD as a good company, but I couldn't figure out the margin of safety.  I'm not even positive it existed.  A 30% premium is mostly a takeover premium and doesn't exactly reflect the idea that I missed some hidden value (this is just a gut feeling).  I think noting that a founder/CEO with a decent inside ownership is not always a de facto sign that they are running the company really well, something to look out for with large cap tech as well.  Obviously TPG sees room to better the operations and they aren't exactly paying a cheap price at 22x earnings.  A new CEO can be a catalyst for public shareholders, although I'm reluctant to believe it's always a positive one.

The new CEO ran a company that was acquired.  When I saw that Immucor had a new CEO, my interest was rekindled.  A new CEO can mean tons of things.  I saw that the new CEO was the former CEO of Mentor (the breast implant maker) that got acquired by JNJ a few years back.  Could I interpret this as a sign that the CEO didn't have the typical CEO ego of wanting to not be his own boss?  I could, but I don't have industry contacts or the scuttlebutt ability to figure out if that really was true.  He did stay at Mentor for 2 years as a subsidiary company.  I'm reluctant to read into this too much since it just confirms what I want to believe.  It certainly meant that some change would occur at the company, although it's difficult to say it would be an acquisition without hindsight.  Certainly the speed indicates that TPG probably was looking at the company before the CEO change, at least beyond preliminary stages.  The CEO change probably gave them the courage to step forward with a bid.  This is all back room kind of dealing though, which is not the basis of an investment process.  It looks hard to do if you aren't a professional.

I can think of one good example of looking at a CEO change as a positive catalyst, although it clearly is based on a lot of research that is scuttlebutt.  The hedge fund manager who had lunch with Warren Buffett after sending him stock research focused on a management change to make a profitable investment in Fiat (source):

"Sergio Marchionne, the new CEO, was a guy with a track record for creating value in Switzerland. He spent time in GE and made his mark at a Swiss quality control company.  He came into a company [Fiat] whose reputation was tarnished and whose brand equity had been decimated. But philosophically smart people choose smart businesses. Marchionne saw the opportunity, and we saw Marchionne.  We were likely the only investors outside Italy interested in Marchionne at the time. After some begging and pleading, he granted us a meeting.  Marchionne joined Fiat with a mandate to do whatever was necessary to fix the company. We bought some shares. He confirmed what we surmised. He had full support of the board and its new chairman. If auto was worth more dead than alive, he'd kill it.  Fiat was the biggest employer in Italy at the time. He took on the labor unions. He was fearless. He had real skin in the game and his incentives were aligned.  Marchionne saved Fiat. He got $2.25 billion to cancel a legacy agreement that Fiat could "put" itself to GM. No one thought it could happen -- there's no way this debt-laden, cash strapped Italian company will win in an international court of law. But Marchionne walked away with $2.25 billion of cash and Rick Wagoner [then CEO of GM] was fired shortly thereafter. This was half of Fiat's market cap.  We exited the position in the mid-teens and made a lot of money. It was the biggest profit generator in Brahman's history."

I can see how this process can work out well, but as you can see from the manager's explanation, it was based in part on meeting the guy.  I'm unaware how an amateur investor could access the information pipeline to figure out what exactly Marchionne did at GE and the Swiss quality control company.

I'm not a fan of the anecdotal nuggets that get released in journalistic reporting, which is the one way I think an amateur could access this kind of information.  I remember when Ken Lewis was touted as a great integrator who had a successful track record pre-CEO integrating some bank into BofA.  Profiles of CEOs tend to be fairly glowing because no CEO would grant an interview to a journalist looking to expose how poorly they do their job.

Did I miss a quick 30% gain?  Yes.  Did I make a mistake?  Maybe, but I'd lean closer to the no end of the spectrum.  The acquisition angle is speculative, although BLUD had merit as an investment.

Does anyone have any other good or bad examples of a CEO change going unnoticed but being a catalyst to the up or downside?  Ford comes to mind although there were serious survival issues when the company was trading at $2/share.

Friday, March 25, 2011

Immucor - Strong Razor and Blades Franchise looks cheap

Immucor (BLUD) is high quality stock that was formerly an expensive growth stock that the market deemed worth >30 times earnings for the better part of the past decade.  The company manufactures machines that perform various blood tests and sell the reagents that are required for each test.  There are only 2 other companies – a subsidiary of Johnson & Johnson and Bio-Rad – that offer a full line of reagents and testing machines.   The stock is not exactly trading for a distressed price, but the current price might allow a patient investor to cheaply purchase shares in a strong franchise with strong long term growth potential.

The company currently trades at 16x TTM earnings and 13x TTM earnings if you net out the cash ($84m in TTM net income, $1.35 mkt cap, $.25bn cash).  On the face, this is not the kind of multiple that attracts a value investor, but investing is not done solely based on one statistic.  The company has a cash adjusted TTM ROE of 33% and a ROIC of 30% achieved with no leverage and minimal cap ex requirements.  The company achieves these great returns through its business model and competitive advantage.

The company sells its machines in order to get long-term contracts guaranteeing the purchase of reagents by customers at a fixed price.  These contracts usually secure annual price increases as well. This is a genuine razors and blades business model.  The reagents (blades) garner 80% gross margins.  Once the company sells or rents a machine to a customer, they are guaranteed a steady stream of high margin revenue.  Recently, the company began disclosing how many machines it has placed that are generating revenue.  Just between August 2010 and November 2010, the companies placed machines grew from 1392 to 1,478.  While I wouldn’t extrapolate this growth, the company is still placing new machines which will drive the top and bottom line.

The growth in the business was phenomenal from 2005-2010, with earnings and revenue doubling and powering right through the recession.  Growth has slowed down in the recent year, despite more machines being placed with customers and a healthy backlog.  The company states that many of the blood tests its products perform have a discretionary component.  According to the CEO, 51% of transfusions are for cardiovascular disease and skeletal diseases (joint and hip replacements).  These are generally procedures that are associated with the elderly.  While people have been putting off what procedures they can, the sheer volume of baby boomers will begin to move the needle along with the increased machine placement. 

There are several risks thought with this company.  The Department of Justice recently dropped an investigation in price fixing and monopolistic behavior on behalf of the company and Johnson & Johnson.  While this investigation was dropped, it spawned a class action lawsuit on behalf of several customers.  The company’s products are a small part of the overall cost structure of their operations, but the company and its competitors are well aware that they serve a crucial and essential function.  While one takeaway would be that the company has a very strong moat, there are some signs that it could as a result of illegal practices.  I’m not a legal expert.  These cases can go either way, although its no surprise to see customers annoyed by the high prices they pay and the lack of alternatives. 

Another risk is a not yet resolved issue with the company’s manufacturing facilities.  The FDA has inspected the facility and not been entirely satisfied.  While the company has taken measures to fix the problems brought up by the FDA, issues still remain.  It would be very difficult to shut down the company though because it does not carry a lot of excess inventory and its products play a crucial role in the day-to-day operations of hospitals.  The details of the issues are not disclosed, but the company has been improving its facilities and there would be a large disruption in many hospitals if the company was forced to cease production at its facilities.

For a patient investor willing to tolerate the downturn in the cycle, the combination of increasing machine placement and increasing long term demand could potentially prove profitable.  An additional long-term driver of growth is the company’s somewhat unique automation strategy.  Their “edge” relative to competitors is that its machines don’t require a full time skilled technician to analyze blood samples and results.  This minimizes errors as well as reduces the labor costs of the blood banks, labs, and hospitals that are its main customers.  An additional catalyst in the stock could be the involvement of ValueAct, a hedge fund whose involvement in another company I have touched upon before.  This collection of attractive long-term characteristics will likely allow the company to overcome the short-term bumps it has encountered in its growth trajectory as well as legal and operational difficulties.

Disclosure: None

Talk to Andrew about Immucor